Electrical stimulation of the auricular vagus nerve (aVNS) is an emerging technology in the field of bioelectronic medicine with applications in therapy. Modulation of the afferent vagus nerve affects a large number of physiological processes and bodily states associated with information transfer between the brain and body. These include disease mitigating effects and sustainable therapeutic applications ranging from chronic pain diseases, neurodegenerative and metabolic ailments to inflammatory and cardiovascular diseases. Given the current evidence from experimental research in animal and clinical studies we discuss basic aVNS mechanisms and their potential clinical effects. Collectively, we provide a focused review on the physiological role of the vagus nerve and formulate a biology-driven rationale for aVNS. For the first time, two international workshops on aVNS have been held in Warsaw and Vienna in 2017 within the framework of EU COST Action "European network for innovative uses of EMFs in biomedical applications (BM1309)." Both workshops focused critically on the driving physiological mechanisms of aVNS, its experimental and clinical studies in animals and humans, in silico aVNS studies, technological advancements, and regulatory barriers. The results of the workshops are covered in two reviews, covering physiological and engineering aspects. The present review summarizes on physiological aspects - a discussion of engineering aspects is provided by our accompanying article (Kaniusas et al., 2019). Both reviews build a reasonable bridge from the rationale of aVNS as a therapeutic tool to current research lines, all of them being highly relevant for the promising aVNS technology to reach the patient.

Electrical stimulation of the auricular vagus nerve (aVNS) is an emerging electroceutical technology in the field of bioelectronic medicine with applications in therapy. Artificial modulation of the afferent vagus nerve – a powerful entrance to the brain – affects a large number of physiological processes implicating interactions between the brain and body. Engineering aspects of aVNS determine its efficiency in application. The relevant safety and regulatory issues need to be appropriately addressed. In particular, in silico modeling acts as a tool for aVNS optimization. The evolution of personalized electroceuticals using novel architectures of the closed-loop aVNS paradigms with biofeedback can be expected to optimally meet therapy needs. For the first time, two international workshops on aVNS have been held in Warsaw and Vienna in 2017 within the scope of EU COST Action “European network for innovative uses of EMFs in biomedical applications (BM1309).” Both workshops focused critically on the driving physiological mechanisms of aVNS, its experimental and clinical studies in animals and humans, in silico aVNS studies, technological advancements, and regulatory barriers. The results of the workshops are covered in two reviews, covering physiological and engineering aspects. The present review summarizes on engineering aspects – a discussion of physiological aspects is provided by our accompanying article (Kaniusas et al., 2019). Both reviews build a reasonable bridge from the rationale of aVNS as a therapeutic tool to current research lines, all of them being highly relevant for the promising aVNS technology to reach the patient.

Internet of Things (IoT) technology offers opportunities to monitor lifelogging data by a variety of assets, like wearable sensors, mobile apps, etc. But due to heterogeneity of connected devices and diverse human life patterns in an IoT environment, lifelogging personal data contains huge uncertainty and are hardly used for healthcare studies. Effective validation of lifelogging personal data for longitudinal health assessment is demanded. In this paper, lifelogging physical activity (LPA) is taken as a target to explore how to improve the validity of lifelogging data in an IoT enabled healthcare system. A rule-based adaptive LPA validation (LPAV) model, LPAV-IoT, is proposed for eliminating irregular uncertainties (IUs) and estimating data reliability in IoT healthcare environments. A methodology specifying four layers and three modules in LPAV-IoT is presented for analyzing key factors impacting validity of LPA. A series of validation rules are designed with uncertainty threshold parameters and reliability indicators and evaluated through experimental investigations. Following LPAV-IoT, a case study on a personalized healthcare platform myhealthavatar connecting three state-of-the-art wearable devices and mobile apps are carried out. The results reflect that the rules provided by LPAV-IoT enable efficiently filtering at least 75% of IU and adaptively indicating the reliability of LPA data on certain condition of IoT environments.

A novel method for QRST cancellation during atrial fibrillation (AF) is introduced for use in recordings with two or more leads. The method is based on an echo state neural network which estimates the time-varying, nonlinear transfer function between two leads, one lead with atrial activity and another lead without, for the purpose of canceling ventricular activity. The network has different sets of weights that define the input, hidden, and output layers, of which only the output set is adapted for every new sample to be processed. The performance is evaluated on ECG signals, with simulated f-waves added, by determining the root mean square error between the true f-wave signal and the estimated signal, as well as by evaluating the dominant AF frequency. When compared to average beat subtraction (ABS), being the most widely used method for QRST cancellation, the performance is found to be significantly better with an error reduction factor of 0.24-0.43, depending on f-wave amplitude. The estimates of dominant AF frequency are considerably more accurate for all f-wave amplitudes than the AF estimates based on ABS. The novel method is particularly well suited for implementation in mobile health systems where monitoring of AF during extended time periods is of interest.